- BrightInsight is a leader in digital health solutions, focusing on AI-enabled medication persistence and adherence, addressing the critical issue of medication non-adherence in the healthcare system.
- In January 2026, BrightInsight secured a multi-million dollar investment of $13 million to enhance its AI-driven solutions and appointed three new executives to its leadership team to accelerate global growth.
- The company has formed strategic partnerships with major players like Sanofi and Regeneron, notably developing a Patient App that has shown positive impacts on treatment adherence.
- BrightInsight's ideal buyers are pharmaceutical companies and healthcare providers looking to improve patient adherence and reduce the economic burden of medication non-compliance, making it a timely opportunity for sales engagement.
Engineering is the largest function with 44 employees, about 42% of the company. Business Management has 14, Marketing and Product has 11, and Sales and Support has 9, reflecting a balanced mix of product development and go-to-market capabilities. Consulting (6) and Information Technology (5) contribute delivery and infrastructure expertise, while Operations (4), Finance and Administration (4), and Legal (2) round out corporate functions. An additional 6 employees are categorized as Other.
BrightInsight’s team is distributed across many locations, with 60 employees classified under Other, representing roughly 57% of headcount. Among named hubs, San Francisco (15) holds the largest share, followed by New York (7) and San Jose (7); smaller groups are in Chicago (4), Austin (3), Sunnyvale (3), Boston (2), London (2), and Minneapolis (2). This footprint spans multiple U.S. cities with a small presence in the UK.
